13.05.2011 • News • Formosa Petrochemicals • Formosa • plant closure

Fire Shuts 2 Units At Formosa Petrochemicals Taiwan Plant

A fire at Formosa Petrochemical Corp's Mailiao plant in central Taiwan has forced the shutdown of ethylene and aromatics facilities, the company said on Friday.

A spokesman said the fire, in a pipe that feeds raw materials to the units, had been put out at around 5:45 a.m. on Friday after breaking out on Thursday evening.

Because of the damage to the pipeline, facilities producing ethylene and aromatics had been shut down, although they were not damaged by the fire, the spokesman said. One of the facilities is operated by Formosa group company Formosa Chemicals & Fibre Corp.

The Mailiao complex was hit by two fires in a month last July, raising concern over its safety record.

Formosa Petrochemical shares fell 2.5% in early trading, while Formosa Chemical fell 2.3%. The broader market was flat.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
28.07.2025 • News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.